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a b s t r a c t
Monocytes and macrophages are key mediators of inﬂammation in rheumatoid arthritis (RA). Their
persistence at the inﬂammatory site is likely to contribute to immunopathology. We sought to charac-
terise one mechanism by which persistence may be achieved: resistance to apoptosis and the role of mir-
155 in this process. CD14þ monocytes from peripheral blood (PBM) and synovial ﬂuid (SFM) of RA
patients were found to be resistant to spontaneous apoptosis relative to PBM from healthy control (HC)
individuals. RA SFM were also resistant to anti-Fas-mediated apoptosis and displayed a gene expression
proﬁle distinct from HC and RA PBM populations. Gene expression proﬁling analysis revealed that the
differentially expressed genes in RA SFM vs. PBM were enriched for apoptosis-related genes and showed
increased expression of the mir-155 precursor BIC. Following identiﬁcation of potential mir-155 target
transcripts by bioinformatic methods, we show increased levels of mature mir-155 expression in RA PBM
and SFM vs. HC PBM and a corresponding decrease in SFM of two predicted mir-155-target mRNAs,
apoptosis mediators CASP10 and APAF1. Using miR mimics, we demonstrate that mir-155 over-expres-
sion in healthy CD14þ cells conferred resistance to spontaneous apoptosis, but not Fas-induced death in
these cells, and resulted in increased production of cytokines and chemokines. Collectively our data
indicate that CD14þ cells from patients with RA show enhanced resistance to apoptosis, and suggest that
an increase in mir-155 may partially contribute to this phenotype.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Monocytes and macrophages are key players in rheumatoid
arthritis (RA) (reviewed in Ref. [1]). CD14þ monocytes from the
peripheral blood (PBM) and CD14þ cells from the synovial ﬂuid of
patients with RA (likely consisting of monocytes and macrophages
and henceforth referred to as SFM) have an activated phenotype
[2e5] and produce pro-inﬂammatory cytokines such as IL-1b and
TNF-a [5e7]. SFM can differentiate to osteoclasts that mediate bone
erosion [8e10] and have also been shown to promote production of
the osteoclastogenic cytokine IL-17 by CD4þ T cells [2,4]. The
importance of the role ofmacrophages in RA is further supported by
the observation that the degree of joint destruction correlates with
synovial macrophage inﬁltration [11] and that successful therapy is
associated with a decrease in synovial lining macrophages [12].
Studies in mice have shown that defects in monocyte apoptosis
result in enhanced systemic inﬂammatory arthritis [13]. Various
death receptors are important in mediating monocyte/macrophage
apoptosis including Fas, TRAIL-R and TNF-R1. Binding of these re-
ceptors leads to recruitment of intracellular adaptor proteins,
which in turn activate caspase-8/10. This forms the extrinsic
apoptosis pathway. In contrast, the intrinsic apoptosis pathway,
which results from intracellular stresses, leads to mitochondrial
permeabilisation and formation of the ‘apoptosome’ consisting of
cytochrome c, Apaf1 and caspase-9. Both pathways lead to down-
stream caspase cascade activation resulting in cell death (reviewed
in Refs. [14,15]).
It has previously been shown that SFM from patients with RA
are resistant to apoptosis mediated by an agonistic anti-Fas anti-
body [16] and have increased expression of the intracellular anti-
apoptotic proteins Mcl-1 and FLIP [16,17]. Previous work from our
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laboratory has shown that RA SFM are also resistant to Fas-
mediated killing by CD4þCD25 responder T cells, which can ex-
press FasL and induce Fas in CD14þ monocytes [18]. In addition,
PBM from RA and Juvenile Idiopathic Arthritis (JIA) patients are
resistant to spontaneous apoptosis [19,20]. This resistance to cell
death may lead to persistence of inﬂammatory monocytes and/or
macrophages thereby perpetuating joint inﬂammation.
MicroRNAs (miRNAs) are genomically encoded small RNA mol-
ecules that are present in all multi-cellular organisms and are
involved in a wide range of developmental and cellular processes.
Following sequential cleavage of a long primary RNA transcript, the
19e22 bp mature miRNA is incorporated into the RNA-induced
silencing complex (RISC). The miRNA then binds to target sites in
30 untranslated regions of messenger RNA (mRNA) while the pro-
tein RISC complex inhibits translation of the mRNA (reviewed in
Ref. [21]). Each miRNA is bioinformatically predicted to target
hundreds of mRNA molecules. Although the degree of repression
observed for each mRNA is usually small, miRNAs are believed to
impact on speciﬁc phenotypes by targeting multiple mRNAs within
a pathway or network of genes [22].
MiRNAs are inﬂuential mediators of monocyte-driven inﬂam-
mation. In humanmonocytesmir-146a/b,mir-155 andmir-9 are up-
regulated in response toTLR stimulation and regulate targets such as
TRAF6, SHIP-1 and NFKB [23e25]. WhilemiRNAs have been studied
in detail in collagen-induced arthritis (CIA) in mice, fewer reports
exist on miRNAs in RA. The expression of miRNAs has been exam-
ined in RA peripheral bloodmononuclear cells [26,27], CD4þ T cells
[28,29], ﬁbroblast-like synoviocytes [27,30] and synovial tissue [30].
Kurowska-Stolarska et al. reported increased expression of mir-155
in RA SFM compared to PBM and increased pro-inﬂammatory
cytokine production as consequence [31]. The study also
conﬁrmed the immune suppressor SHIP-1 as a target of this miR.
Asmir-155 has been reported to be upregulated in inﬂammation
in general and RA SFM in particular, we sought to investigate
whether there is a direct role for this miRNA in the resistance to
apoptosis of RA SFM. In this report we conﬁrm the ﬁnding that mir-
155 is upregulated in RA SFM compared to RA and HC PBM, and
present data identifying mir-155 as a regulator of monocyte/
macrophage apoptosis.
2. Materials and methods
2.1. Patients and healthy donors
Healthy control individuals were recruited from staff and stu-
dents of King's College London and Guy's Hospital, London. RA and
PsA patients were recruited from the Guy's and St. Thomas' NHS
Foundation Trust Rheumatology out-patient clinics and consented
for donation of PB and where available SF. RA patients fulﬁlled the
2010 ACR/EULAR criteria whilst PsA patients fulﬁlled the classiﬁ-
cation criteria of the Classiﬁcation of Psoriatic Arthritis (CASPAR)
Study Group. All patients had an examination of tender and swollen
joints and disease activity score of 28 joints (DAS28) recorded.
Laboratory investigations included C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR). Demographic and clinical
data are shown in Supplementary Table I. All subjects provided
written informed consent, and ethical approval was granted by the
Bromley Research Ethics Committee.
2.2. Cell isolation
Mononuclear cells were isolated from PB and SF by density
gradient centrifugation using Lymphoprep (PAA Laboratories/GE
Healthcare Life Sciences, Buckinghamshire, UK). CD14þmonocytes
were isolated from PBMC/SFMC using a positive selection kit
(Miltenyi Biotec, Gladbach, Germany) (purity >95%) or by FACS
sorting (purity >98%) on a BDAriaII following staining with an anti-
CD14-APC-Cy7 antibody (Clone HCD14; Biolegend, San Diego, CA,
USA).
2.3. Apoptosis assays
To assess spontaneous apoptosis, MACS isolated CD14þ cells
were plated in a 48-well plate (0.5  106/well) in a ﬁnal volume of
500 mL/well of complete medium (RPMI 1640,10% FCS,1 Pen/Step
(Life Technologies, Carlsbad, CA, USA) and L-glutamine (2 mM, Life
Technologies)) and incubated at 37 C (5% CO2). Apoptosis was
assessed by Annexin/7-AAD staining 17e22 h later. For anti-Fas
antibody mediated apoptosis, freshly isolated or mimic trans-
fected cells were incubated as above with the addition of agonistic
anti-Fas antibody (clone CH11, Merck Millipore, Hertfordshire, UK)
or IgM isotype control (Biolegend) at 50 ng/mL or 200 ng/mL for
17e22 h, followed by Annexin/7-AAD staining. Staining for Annexin
and 7-AAD was performed using an ‘Apoptosis Detection Kit’
(Biolegend or Becton Dickinson). Brieﬂy, following overnight cul-
ture the plate was placed on ice for 15 min and the cells collected,
washed once in FACS buffer (PBS, 0.5% BSA, 0.1% NaN3) and resus-
pended in the supplied Annexin buffer (50 mL). Each sample was
stained with 0.25 mL Annexin-FITC and 1 mL 7-AAD solutions and
incubated at room temperature, in the dark for 15 min. The cells
were then diluted in Annexin buffer up to 250 mL and ﬂuorescence
acquired on a BD FACS Canto within 30 min.
2.4. Microarrays
Total RNA was extracted from isolated CD14þ cells using TRIzol
reagent (Life Technologies) and the aqueous phase further puriﬁed
using RNeasy MinElute Cleanup Kit (Qiagen). RNA integrity was
conﬁrmed on an Agilent 2100 Bioanalyzer using total RNA nano
chips (Agilent Technologies, Santa Clara, CA, USA). A sample was
deemed to be of sufﬁcient quality if it had an RNA Integrity Number
(RIN)  6 paired with a visual inspection of the proﬁle. Total RNA
(100 ng) was used to prepare targets by 30 IVT Express kit (Affy-
metrix, Santa Clara CA, USA) following manufacturer's instructions,
and cocktails hybridized onto Human Genome U133 plus 2 Arrays
(Affymetrix). Chips were scanned and gene expression data were
normalized using the RMA algorithm and the Bioconductor pack-
age “Affy” (http://www.bioconductor.org). A custom chip deﬁnition
ﬁle from brainarray.mbni.med.umich.edu was used for data
extraction and analysis. Data analysis was performed using Qlucore
Omics Explorer 3.0 software (Qlucore AB, Lund, Sweden). The
microarray data are deposited in Gene Expression Omnibus (GEO)
with accession number GSE71370.
2.5. qRT-PCR
Total RNAwas extracted using TriZol reagent (Life Technologies)
and the miRNeasy kit (Qiagen, Hilden, Germany). Mature miRNA
levels were quantiﬁed using MicroRNA RT kit and TaqMan miRNA
assays (Life Technologies) for mir-155 and the housekeeping RNAs
RNU44 and RNU48, following manufacturer's protocols. For
ampliﬁcation of mRNAmolecules, TriZol extracted RNAwas reverse
transcribed using a High Capacity cDNA Reverse Transcription Kit
(Life Technologies) and ampliﬁed using SensiFAST SYBR Green
Master mix (Bioline, London, UK) on an ABI7900HT machine.
2.6. Transfection
Transfection of CD14þ cells was performed using the NTER
nanoparticle transfection reagent (Sigma, St Louis, MO, USA)
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following manufacturer's instructions. The cells were plated
(0.5 106/well, 48-well plate), followed by addition of medium and
the transfection mix to a ﬁnal volume of 250 mL, and thorough
pipette mixing prior to incubation. Transfection efﬁciency was
conﬁrmed by ﬂow cytometry using a scrambled control mimic
conjugated to the ﬂuorescent dye Dy547 (GE Dharmacon, Lafayette,
CO, USA). MiRIDIAN miRNA mimics (ﬁnal concentration 20 nM)
were used for over-expression of miRNA, with a negative control
from the same manufacturer (GE Dharmacon). Apoptosis was
assessed 40 h after transfection.
2.7. Luminex
Culture supernatants were collected at the end of the culture
period and immediately frozen at 80 C. The samples were
thawed and secreted cytokines were measured using a Cytokine
Human 25-plex panel (Life Technologies) on a Luminex platform
following manufacturer's instructions.
2.8. Statistical analysis
Data were tested for normality using the D'Agostino and Pear-
son omnibus normality test where possible. Signiﬁcance testing
was performed using GraphPad Prism 5 software (GraphPad, San
Diego CA, USA). Tests for parametric data were applied where
indicated and where t-tests were used, Welch's correction was
routinely used as some data showed unequal variances. When data
were not normally distributed or when biological replicates were
less than 8, non-parameteric tests were used. One-way ANOVAs
were performed with using Kruskal-Wallis with Dunn's post test.
3. Results
3.1. CD14þ cells from patients with RA show enhanced resistance to
apoptosis
Previous work from our laboratory has reported the resistance
of RA PBM and SFM to Fas-mediated killing by responder T-cells
[18]. To assess if these cells were also resistant to spontaneous
Fig. 1. CD14þmonocytes from patients with RA show enhanced resistance to spontaneous and Fas mediated death. (A) MACS isolated CD14þ cells from the peripheral blood
(PBM) of RA patients and healthy controls (HC) and synovial ﬂuid (SFM) of RA patients were cultured overnight in complete medium and their survival assessed by Annexin/7-AAD
staining, with the double negative population considered ‘live’. Representative data are shown in the left panel and cumulative data for HC vs. RA PBM in the middle panel (unpaired
t-test with Welch's correction), with the correlation (Spearman's R) of spontaneous RA PBM survival at 24 h with patients' DAS28 scores in the right panel. Lines show linear
regression and 95% conﬁdence intervals. (B) Cumulative CD14þ cell survival in unpaired (left panel, unpaired t-test with Welch's correction) and paired (right panel, Wilcoxon
matched pairs signed rank test) RA PBM and SFM. (C, D) PBM and SFM were cultured overnight with medium alone (Cells only) or with an agonistic anti-Fas antibody (aFas) or the
isotype control (IgM) at 200 ng/mL and the percentage of live cells assessed. Representative dotplots (C) and cumulative data (D) are shown (Wilcoxon matched pairs signed rank
test). *p < 0.05, **p < 0.01, ***p < 0.001.
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death, CD14þ cells from the PB of healthy controls (HC) and pa-
tients with RA, and from SF from RA patients were plated in com-
plete medium overnight and their survival quantiﬁed by Annexin/
7-AAD staining. An increase in the percentage of live RA PBM was
observed compared to HC PBM (Fig. 1A). A similar observation was
made in age-matched samples (Supplementary Fig. 1). The per-
centage of live PB-derived monocytes was found to correlate with
the patients' Disease Activity Score (DAS28) and CRP but not with
ESR or disease duration (Fig. 1A and Supplementary Fig. 2). When
we examined RA SFM, a greater percentage of live cells was
detected after overnight culture compared with RA PBM (Fig. 1A
and B, left panels). The increased survival of SF-derived monocytes
appeared less prominent when paired RA PBM/SFM samples were
compared (n ¼ 6, Fig. 1B, right panel), however this may be
explained by an enhanced apoptosis resistance in the PBM of these
patients (average percentage live monocytes 62% in PBM from
paired samples as compared to an overall average of 48%).
We also tested whether CD14þ cells from HC and RA PBM and
RA SFM were resistant to killing by an agonistic anti-Fas antibody
(clone CH-11). While HC and RA PBM were equally susceptible to
killing by the anti-Fas antibody relative to isotype control treated
cells, RA SFM were more resistant (Fig. 1C and D). Similar results
were obtained when paired RA PBM/SFM were compared (n ¼ 4,
data not shown) or when a lower concentration of anti-Fas Ab was
used (50 ng/ml, data not shown). Together these data show that
CD14þ cells from RA patients, particularly those from the inﬂamed
joint, are more resistant to cell death, relative to HC CD14þ cells.
Although both RA PBM and RA SFM showed an increased resistance
to spontaneous cell death, relative to HC PBM, only SFM showed
enhanced resistance to Fas-induced death.
To assess whether this resistance to apoptosis was speciﬁc to RA
or a more general feature of arthritis, we tested a small number of
PBM and SFM from patients with psoriatic arthritis (PsA). While
there was no clear difference in spontaneous or Fas-induced
Fig. 2. Gene expression proﬁling shows decreased expression of pro-apoptotic genes in RA SFM. (A) Principal component analysis plot of the three cell types assessed by gene
expression proﬁling using Affymetrix arrays; healthy donor PB CD14þ cells (HC PBM, magenta), RA patient PB CD14þ cells (RA PBM, blue) and RA patient SF CD14þ cells (RA SFM,
yellow). (B) Pathways that are over-represented in the 3033 differentially expressed genes (DEG, q < 0.05) in RA SFM vs. RA PBM. Pathway analysis was performed using the Panther
database and p-values shown are after Bonferroni correction. The ﬁrst numbered column (indicated by #) shows the number of genes from the DEG list that are classiﬁed in each
pathway. (C, D) Array data showing (C) increased expression of pro-survival genes from the ‘apoptosis signalling pathway’ (highlighted in B) in RA SFM vs. PBM and (D) decreased
expression of pro-apoptotic genes from the same set. (C) and (D) were tested by ANOVA, Kruskal-Wallis test with Dunn's post test. *p < 0.05, **p < 0.01, ***p < 0.001. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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apoptosis between HC PBM and PsA PBM, PsA SFM tended to be
more resistant to both spontaneous and Fas-mediated apoptosis
(Supplementary Fig. 3).
3.2. Gene expression proﬁling shows changes in apoptosis related
genes in RA SFM vs PBM
In order to understand possible changes in gene expression in
the CD14þ cells from the site of inﬂammation compared to their
circulating counterparts, an Affymetrix gene expression proﬁling
study was undertaken examining nine SFM and PBM samples from
patients with RA (of which n ¼ 8 were paired) and eight PBM
samples from age-matched healthy donors. No signiﬁcant differ-
ences were observed between the proﬁles of RA and HC PBM,
although there was considerable variation among the RA PBM
samples. RA SFM however, formed a cluster distinct from both HC
and RA PBM (Fig. 2A) and had 3033 signiﬁcantly differentially
expressed genes (DEG) relative to RA PBM (FDR 0.05) in an un-
paired, two-group comparison. Pathway analysis of these DEG
revealed that genes related to apoptosis signalling were statistically
signiﬁcantly over-represented in this set (Table 1 and Fig. 2B).
Genes related to Fas signalling were also enriched, though not
signiﬁcantly. Among the 30 genes related to apoptosis signallingwe
found increased expression of the pro-survival genes BCL2, BCL2L1
(Bcl-xL), XIAP and TMBIM6 (Bax inhibitor) and decreased expres-
sion of the pro-apoptotic genes BCL2L11 (Bim), APAF1, CASP8 and
CASP10 (Fig. 2C and D). These data show that RA SFM have signif-
icant changes at the gene expression level, relative to PBM, that
may contribute to the observed apoptosis resistance of these cells.
3.3. Mir-155 is highly expressed in RA SFM and may target pro-
apoptotic transcripts
In the gene expression comparison of RA SFM vs. PBM, one of
the most highly differentially expressed transcripts was BIC (B-cell
Integration Cluster), which is the host gene for the microRNA mir-
155, and which showed approximately 47-fold up-regulation in RA
SFM vs. PBM (Fig. 3A). Maturemir-155 levels were also signiﬁcantly
increased in RA SFM relative to RA PBM as determined by qRT-PCR.
Although there was no difference in host gene/BIC expression be-
tween RA and HC PBM, the qRT-PCR results showed signiﬁcantly
increased levels of mature mir-155 in RA PBM (Fig. 3B). Similarly,
PsA SFM also showed signiﬁcantly increased levels of mature mir-
155 relative to HC and PsA PBM, however there was no difference
inmaturemir-155 levels between HC and PsA PBM (Supplementary
Fig. 4).
As mir-155 is a well-studied miRNA in monocyte inﬂammation
and since miRNAs function by regulating the expression of mRNA
molecules, we sought to explore if there was a relationship be-
tween this miRNA and resistance to apoptosis in monocytes from
RA patients. To identify potential mRNA targets of mir-155, we used
predictions obtained from four different software programs (Tar-
getScan, MiRanda, MicroCible and RNA22). Only those targets that
were predicted by at least 3 of the 4 programs (Fig. 3C, circled) were
included in further analysis. This list of predictions was then
compared with the list of genes that were signiﬁcantly down-
regulated in the RA SFM vs. PBM microarray analysis, and that
were apoptosis-related according to gene ontology analysis
(Table 1). This analysis resulted in the identiﬁcation of four candi-
date genes that are predicted targets of mir-155, are down-
Table 1
Genes that are signiﬁcantly differentially expressed in RA SFM (vs. RA PBM) and are classiﬁed as related to ‘apoptosis signalling’ by Panther
gene ontology database. Gene ontology and pathway analysis was performed on the 3033 differentially expressed genes between RA SFM and
PBM using the Panther database (www.pantherdb.org). Using this tool a statistical overrepresentation test was performed and the resulting
panther pathways categories after a Bonferroni analysis for multiple testing are shown in Fig. 2B. The genes in the category ‘apoptosis signalling’
are shown in this table, separated by those increased in SFM vs. PBM and those that are decreased.
Gene symbol Gene name
Increased in SFM vs. PBM
HSPA1A Heat shock 70 kDa protein 1A
BCL2L1 BCL2-like 1 (BCL-XL/S)
BAG3 BCL2-associated athanogene 3
MAPK7 Mitogen-activated protein kinase 7 (ERK5)
HSPA6 Heat shock 70 kDa protein 6 (HSP70B)
MAPK8 Mitogen-activated protein kinase 8 (JNK1)
HSPA2 Heat shock 70 kDa protein 2
BCL2 B-cell CLL/lymphoma 2
TNFRSF10D TNF Receptor Superfamily, Member 10d, decoy with Truncated Death Domain (TRAIL4)
XIAP X-linked inhibitor of apoptosis
MAP4K3 Mitogen activated protein kinase kinase kinase kinase 3
CASP7 Caspase-7, apoptosis-related cysteine peptidase
TMBIM6 Transmembrane BAX inhibitor motif containing 6
ATF2 Activating transcription factor 2 (CREB2)
HSPA5 Heat shock 70 kDa protein 5 (glucose regulated protein 78 kDa)
PIK3CB Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
Decreased in SFM vs. PBM
HSPA1L Heat shock 70 kDa protein 1-like
LTB Lymphotoxin beta (TNF superfamily, member 3) (TNFSF3)
PRKCB Protein kinase C, beta
MAP4K2 mitogen-activated protein kinase kinase kinase kinase 2
FOS FBJ murine osteosarcoma viral oncogene homolog
CASP10 caspase 10, apoptosis-related cysteine peptidase (ALPS2, FLICE2)
CASP8 caspase 8, apoptosis-related cysteine peptidase (ALPS2B, FLICE)
BCL2L11 BCL2-Like 11 (Apoptosis Facilitator) (BIM)
APAF1 Apoptotic Peptidase Activating Factor 1
MAP3K5 Mitogen-activated protein kinase kinase kinase 5
BAG4 BCL2-associated athanogene 4
PIK3CD Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
TP53 Tumor protein p53
TNFRSF10C Tumor Necrosis Factor Receptor Superfamily, Member 10c, decoy without an intracellular domain
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regulated in RA SFM and are known to be apoptosis-related. These
genes were APAF1, CASP10, FOS and PRKCB. These genes were also
found to be down-regulated in a recently reported independent
gene expression proﬁling study examining the same cell types [32].
Of these four, APAF1 and CASP10 have been reported to be directly
involved in apoptosis and decreased expression of their transcripts
in RA SFM vs. RA PBM was conﬁrmed by qRT-PCR in a set of in-
dependent samples (Fig. 3D). Together, these data suggest a po-
tential direct role for mir-155 in monocyte/macrophage apoptosis
through regulation of these two candidate transcripts.
3.4. Mir-155 over-expression increases survival and inﬂammatory
potential of CD14þ cells
To test the effect of increased mir-155 levels on CD14þ cell
survival, miRNAmimics were used to overexpress either mir-155 or
a non-targeting negative control in healthy PB CD14þ cells by
transfection. Successful transfection was conﬁrmed by ﬂow
cytometry of cells transfected with a ﬂuorescent molecule (Dy547)
conjugated mimic and showed that on average, 50% of the cells
were transfected (Fig. 4A). Speciﬁc over-expression of mir-155 was
conﬁrmed by qRT-PCR in cells transfected with either the negative
control, mir-155 mimic or mock transfected (Fig. 4B). Over-
expression of mir-155 in healthy CD14þ monocytes signiﬁcantly
(17/22 experiments) increased the survival of these cells following
40 h culture, relative to control-transfected cells (Fig. 4C and D). A
non-speciﬁc survival enhancing effect of the negative control
mimic transfection was also observed (percentage of live cells
following Mock 25% vs. Neg Control 41%, data not shown) however
the cells transfected with mir-155 mimic had higher survival than
either of these conditions (61%), indicating a speciﬁc, survival
enhancing effect of mir-155. When mimic transfected cells were
subjected to killing by the agonistic anti-Fas antibody (vs. control
IgM) there was no survival beneﬁt conferred by enhanced mir-155
expression (Fig. 4E).
In addition to increased survival, Luminex analysis revealed that
over-expression of mir-155 in healthy CD14þ cells led to elevated
expression of a range of chemokines and cytokines (Fig. 5). These
included the chemoattractants MCP-1 (CCL2), MIP-1a (CCL3), MIP-
1b (CCL4), IL-8 (CXCL8) and IP-10 (CXCL10) and the cytokines IFN-a,
IL-6, IL-12, IL-15 and IL-7. IL-1Ra was also consistently increased.
Soluble IL2R, IL-1b, TNF-a, IL-10 and RANTES were increased in
some but not all samples, while the rest of the tested cytokines
(IFN-g, IL-4, IL-2, IL-17, Eotaxin, GM-CSF, IL-13, IL-5 and MIG, not
shown) were not in the detectable range in any of the conditions.
4. Discussion
Monocytes and macrophages have a central role in the inﬂam-
matory processes in RA [1]. Here we propose that RA PBM and SFM
may sustain this role through increased resistance to death and
provide evidence that one of the factors that may assist in
orchestrating this death resistance is the microRNA mir-155.
Two previous studies have reported on the resistance to spon-
taneous death of PBM of arthritic patients; the ﬁrst examined PB
CD33þCD3- cells from JIA patients in low-serum medium [20],
while the second examined RA PBM in the presence of a control IgG
antibody and low serum [19]. In our study, we tested highly pure
preparations of RA PBM in 10% serum medium and no other
additions.
Fig. 3. Mir-155 is increased in RA CD14þ cells and may target apoptosis genes. (A) Levels of the mir-155 precursor transcript BIC in HC PBM, and in RA PBM and RA SFM as
assessed by gene expression proﬁling. (B) Levels of mature mir-155 were measured by TaqMan microRNA assay from total RNA isolated from FACS sorted PBM and SFM. Results were
normalised to the small nucleolar RNA RNU48. HC PBM vs. RA PBM and HC PBM vs. RA SFM tested by Mann Whitney test; paired RA PBM vs SFM tested by Wilcoxon matched-pairs
signed rank test. (C) Predicted targets of mir-155 from four software programs were overlapped and those predicted by all four and a combination of any three of the four were
identiﬁed (circled). (D) Expression levels of the apoptosis-related genes APAF1 and CASP10 were measured by qRT-PCR in HC PBM (n ¼ 6) and RA PBM (n ¼ 7) and SFM samples
(n ¼ 6). Expression was normalised to the housekeeping gene SDHA. Multiple groups were tested by one-way ANOVAwith Tukey's (A) or Dunn's post test (D). *p < 0.05, **p < 0.01,
***p < 0.001.
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Additionally, we demonstrate that RA SFM show enhanced
resistance to spontaneous death relative to both HC and RA PBM,
although this difference was lost when comparing PBM and SFM
from the same patients in a small set of samples. The latter may be
explained by enhanced apoptosis resistance in the PBM of these
patients, which could potentially be due to a ﬂare in disease ac-
tivity. While this study was not speciﬁcally designed to assess any
potential differences between PBM from patients who are or not
undergoing a ﬂare, the observation suggests that such acute in-
ﬂammatory events may inﬂuence monocyte survival. In agreement
with previous reports [16,18], SFM were also found to be resistant
to Fas-mediated death, induced by an agonistic anti-Fas antibody.
The resistance to spontaneous and Fas-mediated death of SF-
derived CD14þ cells may be a general feature of cells from the
site of active inﬂammation in arthritis, since similar observations
were made in PsA. Therefore, CD14þ cells from the inﬂamed joint
appear to be resistant to death by both the extrinsic (death re-
ceptor) and intrinsic pathways of apoptosis.
One explanation for the observed relationship between
increased monocyte survival and enhanced disease activity in RA is
that systemic inﬂammatory factors may inﬂuence the susceptibility
of monocytes to apoptosis induction. Alternatively, it is possible
that monocytes/macrophages from patients with RA harbour
intrinsic changes that drive both inﬂammation and resistance to
apoptosis. Currently, it is not possible to discriminate between
these two possibilities and both may occur in parallel.
In order to determine a possible molecular basis for the
observed resistance to apoptosis, we undertook gene expression
proﬁling to assess the differences between CD14þ cells from PB and
SF. Although the proﬁling showed no statistically signiﬁcant
Fig. 4. Increased mir-155 promotes monocyte survival. (A) Healthy donor monocytes were transfected with a negative control miRNAmimic conjugated to a ﬂuorescent molecule
Dy547. Following incubation for 40 h, Dy547 positive cells were assessed by ﬂow cytometry. (B) Monocytes were transfected with mir-155 mimic or negative control mimic (Neg
Ctrl), or with transfection reagent only (mock) and incubated for 40 h. Mature mir-155 levels were measured using a TaqMan microRNA assay. (C, D) Representative plots (C) and
cumulative data (D, n ¼ 22) showing healthy donor CD14þ monocyte survival 40 h after transfection with negative control mimic (Neg Ctrl) or mir-155 mimic. (E) Healthy donor
monocytes were transfected (n ¼ 7) with Neg Ctrl or mir-155 mimic for 24 h followed by overnight culture with an agonistic anti-Fas antibody (aFas) or the isotype control (IgM) at
200 ng/mL and the percentage of live cells assessed. D and E tested by Wilcoxon matched-pairs test.
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differences between PBM from RA patients and HC donors, as a
whole, a notable feature of the gene expression proﬁling was the
great degree of variationwithin the RA PBM samples (Fig. 2). Due to
this variation in RA PBM but not HC PBM, we cannot deﬁnitively
conclude that there is no difference between HC and RA PBM, or
between subsets of RA patients. A repeat microarray experiment
with a larger number of samples would be necessary to establish
this. Interestingly, the variation within the RA PBM group is also
reﬂected in the spontaneous apoptosis results (Fig. 1). These data
also show large variation between patients' monocyte survival,
with some of the RA PBM samples showing greatly increased sur-
vival compared to the majority of the HC PBM samples, whilst
several other RA PBM samples clearly fall within the range
observed in HC PBM.
The RA SFM gene expression proﬁle however was clearly
distinct. The differentially expressed genes in SFM (vs. PBM) were
enriched for genes related to apoptosis signalling, an observation
that supports our ﬁndings. While previous studies have reported
increased expression of the proteins FLIP and MCL1 in RA SFM
[16,17], we found no signiﬁcant differences in transcript levels of
these molecules between the groups in our microarray data (not
shown).
One of the most highly differentially expressed genes in RA SFM
was the mir-155 host gene (also known as BIC). We show that the
levels of mature mir-155 were also increased in RA SFM relative to
RA PBM, supporting a previous report [31], and in RA PBM, relative
to HC PBM, thus conﬁrming a recent study [33]. The increase in
mature mir-155 levels in SFM was also conﬁrmed in PsA
CD14þ cells (Supplementary Fig. 4). Therewas no difference in mir-
155 levels between HC and PsA PBM, a ﬁnding that reﬂects the lack
of difference in spontaneous monocyte survival between these two
groups.
Mir-155 is highly conserved (present in all jawed vertebrates
[34]) and is one of the best studied miRNAs in leukocytes. BIC and
mature mir-155 were ﬁrst reported as highly expressed in B-cell
lymphomas [35] and have since been found to be involved in a
range of cancers (reviewed in Ref. [36]). In cells of the monocyte/
macrophage lineage, mir-155 is induced upon TLR ligation with
various ligands [31,37,38] and is involved in both positive and
negative regulation of inﬂammation through mechanisms
including repression of the immunemodulators SHIP-1 [25], SOCS1
[39] and BCL6 [40].
Dysregulation of mir-155 has been observed in human auto-
immunity, with increased levels reported in active ulcerative colitis
(vs. HC) [41] and in multiple sclerosis CNS tissue [42]. In RA,
increased expression of mir-155 has been reported in PBMC, sy-
novial ﬁbroblasts and synovial tissue [26,27,30] and in RA SFM, in
which it represses SHIP-1 [31]. In addition, mir-155 (whole-or-
ganism) knockout mice were found to be resistant to CIA [31,43].
Our ﬁndings in this study of increasedmir-155 levels in RA SFM and
PBM and a pro-survival and pro-inﬂammatory role are therefore
consistent with existing literature. We can also conﬁrm a decrease
Fig. 5. Mir-155 over expression leads to increased monocyte cytokine/chemokine production. Culture supernatants from healthy donor monocytes transfected with negative
control (Neg Ctrl) or mir-155 mimic (as described in Fig. 4) were analysed using a Cytokine Human 25-plex Luminex assay; n ¼ 6. Cytokines that were above the lower detection
limit for at least 1 of the samples are shown. The dashed line shows the lower detection limit for the analyte, while the dotted line shows the upper detection limit.
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in INPP5D (encoding SHIP-1) levels in RA SFM corresponding with
an increase in mir-155 levels in these cells (Supplementary Fig. 5).
One of the major bottlenecks in miRNA target discovery is the
sheer number of mRNAs that are bioinformatically predicted for
each miR, and the relatively low level of overlap between the
predictions of each program. To circumvent these issues we chose
to consider predictions made by at least three of four programs,
thus identifying four candidates that are apoptosis related and are
down-regulated in RA SFM in microarrays done by us as well as
microarrays performed independently by another group [32].
Down-regulation of two candidate genes, APAF1 and CASP10, in RA
SFM was conﬁrmed by q-RT-PCR. The genes APAF1 and CASP10 are
both known players in apoptotic processes and represent the two
apoptosis pathways: the extrinsic or death receptor mediated
pathway (CASP10) and the intrinsic or mitochondrial pathway
(APAF1).
Mimicking the mir-155 over-expression seen in RA SFM by
transfecting HC PBM to over-express this miR resulted in signiﬁ-
cantly increased survival of these cells. A direct effect of mir-155 on
spontaneous cell survival has not previously been shown. In
contrast, mir-155 overexpression did not enhance survival of
monocytes upon addition of the agonistic anti-Fas antibody, sug-
gesting that the effect of mir-155 may be restricted to the intrinsic
pathway and APAF1.
Further investigation by PCR of expression of APAF1 in cells from
mimic transfected wells did not show a consistent decrease in
transcript levels after mir-155 mimic transfection (Supplementary
Fig. 6). However, this may not be surprising; a lack of effect of
mir-155 on APAF1 transcript, but an observable effect on protein
level, has been reported previously in a study that conﬁrms APAF1
as a target of mir-155, albeit in a different context [44]. We did not
observe a consistent effect on CASP10 transcript, but did note a
decrease in INPP5D expression in mir-155 mimic transfected
monocytes at 24 hours. This difference was not seen at 40 hours,
the time point at which monocyte survival was assessed. This in-
dicates the possibility of other factors coming into effect at this later
time point rendering it difﬁcult to measure the effect on the tran-
script. The INPP5D transcript has been extensively biologically
validated as a target of mir-155 and therefore the lack of a clear
relationship between its expression and mir-155 overexpression
suggests that the chosen method may not be ideal for measuring
this effect. The observed variation could be due to the fact that only
part of the cells (avg. 50%) were transfected with the mimic while
we assessed transcript levels in all the cells in the well. As these
were primary cells, when plated they may be at different stages of
their life cycle, and therefore have had different amounts of target
transcript levels to begin with.
The other signiﬁcant outcome of mir-155 over-expression was
pro-inﬂammatory cytokine production. Previous studies have
shown increased TNF-a in human monocyte-derived macrophages
[42] and increased TNF-a, IL-6, ILe8 and IL-1b in RA PBM [31]
following mir-155 over-expression. We extend these data by
showing that several other cytokines and chemokines (MCP-1, MIP-
1a, MIP-1b, IL-8, and IP-10, IFN-a, IL-6, IL-12, IL-15 and IL-7) are also
upregulated by overexpression of this miR. The changes in cytokine
levels we detected were a direct consequence of mir-155 over-
expression, as no other stimulus was provided to the cells. These
ﬁndings are supported by a recent study that reported a mir-155
mediated increase in the receptors for many of these chemokines
[33]. Although we cannot rule out the possibility that the increase
in detected cytokines could be due to increased numbers of sur-
viving cells, rather than increased production per cell, the resulting
wide-ranging inﬂuence of the inducedmediators suggests a role for
mir-155 in monocyte/macrophage-driven inﬂammatory processes
in RA. For instance, increased SFM production of MIP-1a, MIP-1b,
MCP-1 and IL-8 and increased IL-12, IL-15, IL-7 would recruit
myeloid and lymphoid cells to the joint, respectively.
5. Conclusions
Collectively, our data show increased resistance to cell death in
RA SFM and PBM and a concurrent increase in the expression of
mir-155. We also demonstrate that increased mir-155 expression in
healthy CD14þ cells renders them more resistant to death and
enhances their cytokine/chemokine production These ﬁndings
suggest that the increased expression of mir-155 in PBM and SFM of
patients with RA may contribute to inﬂammation through two
means: ﬁrst, by increasing monocyte/macrophage survival,
possibly by directly repressing expression of pro-apoptotic genes;
and second, by increasing levels of a wide range of pro-
inﬂammatory cytokines and chemokines.
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